​BeneluxBio

Innovating Drug Discovery

Pioneering Solutions for a Healthier Tomorrow

Leading the Way in Drug Innovation
Shaping the Future of Medicine, One Discovery at a Time

Services

Target Identification

Target Identification

Utilizing advanced technologies to identify molecular targets that are crucial in disease pathology, ensuring early and precise intervention.

Compound Screening

Compound Screening

High-throughput screening of chemical compounds to rapidly identify potential drug candidates with therapeutic benefits.

Preclinical Testing

Preclinical Testing

Robust preclinical testing protocols to evaluate drug efficacy and safety, paving the way for successful clinical trials.

WEBSITE  IS UNDER CONSTRUCTION

  • Maastricht, Netherlands
  • Hondertmarck 47 C,6211 MB

Collaborations,Pipeline,Patents

 We turn our projects into products by closing collaborative agreements with Universities,Hospitals, Dutch SME's(Mkb ),Flemish Institutions and Universities located in North-Holland, South-Holland,Brabant,Limburg, Gelderland and Flanders 

 30 investigational new molecular entities are registered at iDEPOT for chemical synthesis and testing in bioassays We have a location in Flanders that supports our operations in the Flemish region ( VLAIO) 

 BeneluxBio BV is a company that develops new drugs for brain diseases and neurological disorders. Its current projects focus on epilepsy, glioblastoma, primary central nervous system lymphoma (PCNSL), and post-neurosurgical CRE meningitis and ventriculitis. CRE stands for carbapenem-resistant Enterobacteriaceae. We use proprietary lead compounds. We are a pharmaceutical research and development company and not a services company. 

 European Innovation programme South Netherlands 

 With support from the European Union Medegefinancierd door de Europese Unie 

 Discovered, developed and produced in the Benelux 

About Us
BeneluxBio BV is a company that develops new drugs for neurological disorders, including cancer and infectious diseases of the brain. We have developed an innovative small-molecule platform technology specifically designed to overcome the biological blood-brain barrier and target the underlying disease mechanisms in the central nervous system (CNS). BeneluxBio consists of a team of four people, each with their own complementary expertise, and a number of advisors. In addition, BeneluxBio is part of a network that emerged following the acquisition of 
Organon. On September 1, 2026, the Shuttle To Brain project was launched, comprising 3 universities, 2 academic hospitals, and 4 SMEs from Belgium, the Netherlands, and Germany. BeneluxBio is one of the 9 partners .